Can I Take CoQ10 with Vyleesi (Bremelanotide)?

What Is Bremelanotide (Vyleesi) and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It binds melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system, with MC4R activation in the hypothalamus considered the primary driver of increased sexual desire. The drug does not act on hormonal axes the way testosterone or estrogen do.

Pharmacokinetics at a Glance

Bremelanotide is delivered via a 1.75 mg subcutaneous auto-injector to the abdomen or thigh. Peak plasma concentration (Cmax) is reached in roughly 1 hour, with a mean half-life of 2.7 hours. The drug is metabolized through hydrolysis of peptide bonds, not through cytochrome P450 (CYP) enzymes, which is clinically significant: because CYP1A2, CYP2C9, CYP2D6, and CYP3A4 are not involved, drugs and supplements that inhibit or induce those enzymes do not alter bremelanotide exposure. This pharmacokinetic profile is detailed in the FDA prescribing information and the phase 2 dose-finding data published by Clayton et al. [1][2].

The Transient Blood Pressure Effect

In the key RECONNECT trials (N=1,267 pooled), bremelanotide produced a mean transient increase in systolic blood pressure of approximately 2 mm Hg and diastolic blood pressure of approximately 1 mm Hg, with values returning to baseline within 12 hours of injection [3]. The FDA prescribing label states: "Vyleesi transiently increases blood pressure. The maximum mean increase in systolic blood pressure was 6 mm Hg, occurring at approximately 4 hours after dosing." This BP rise resolves spontaneously without treatment in most women, but it is the reason the label carries a cardiovascular disease contraindication.

What Is CoQ10 and Why Do People Take It?

Coenzyme Q10 (ubiquinone) is a fat-soluble quinone found in every cell's inner mitochondrial membrane. It shuttles electrons between Complex I/II and Complex III of the electron transport chain, and it functions as a membrane-bound antioxidant. Endogenous CoQ10 synthesis declines with age and is markedly reduced by statin therapy, which blocks the mevalonate pathway shared by both cholesterol and CoQ10 biosynthesis [4].

Common Reasons Women Take CoQ10 Alongside Vyleesi

Women prescribed Vyleesi are often in their 30s or 40s and may already be taking CoQ10 for one or more of these reasons:

• Statin therapy (atorvastatin, rosuvastatin) depleting endogenous CoQ10
• Fertility or egg-quality support (doses of 400 to 600 mg/day are sometimes used)
• Migraine prophylaxis (300 mg/day reduced migraine frequency in a randomized trial of 42 patients) [5]
• General antioxidant or energy support at 100 to 200 mg/day

Understanding why a patient is taking CoQ10 helps the clinician assess whether the dose involved is likely to produce a meaningful blood-pressure effect.

CoQ10 and Blood Pressure: What the Data Show

CoQ10 is not a potent antihypertensive, but its effect is measurable. A meta-analysis of 12 randomized controlled trials (N=362) published in the Journal of Human Hypertension found that CoQ10 supplementation reduced systolic blood pressure by a mean of 11.2 mm Hg (95% CI: 8.4 to 14.0 mm Hg) and diastolic blood pressure by 7.7 mm Hg (95% CI: 5.8 to 9.7 mm Hg) at doses ranging from 100 to 225 mg/day [6]. The effect was most pronounced in hypertensive subjects, not in normotensive women.

A Cochrane systematic review of CoQ10 for hypertension cautioned that evidence quality is moderate and that "the blood-pressure-lowering effect appears to depend on baseline blood pressure, with minimal effect in normotensive individuals" [7].

Is There a Drug Interaction Between CoQ10 and Vyleesi?

The short answer: no pharmacokinetic interaction has been identified, and no clinical case reports of a harmful interaction exist in the published literature. The interaction concern is pharmacodynamic and mild.

Pharmacokinetic Interaction: None Expected

As noted above, bremelanotide does not use CYP enzymes for metabolism. CoQ10 similarly does not substantially inhibit or induce major CYP isoforms at doses used clinically. Neither compound is a P-glycoprotein substrate in a way that would change the other's absorption. The Natural Medicines Database rates the CoQ10-bremelanotide interaction as not rated or insufficient evidence, reflecting the absence of any direct interaction data rather than a known risk [8].

Pharmacodynamic Interaction: Possible Additive BP Lowering

Here is where nuance matters. Bremelanotide transiently raises BP for several hours post-injection, while CoQ10 at higher doses exerts a modest sustained antihypertensive effect over weeks of daily use. In a typical dosing scenario, these effects are not synchronous. Women taking CoQ10 in the morning and using Vyleesi in the evening would experience the tail end of any daily CoQ10 cardiovascular effect during the Vyleesi injection window, though the net outcome in normotensive women is unlikely to be clinically significant.

The scenario that does deserve attention: a premenopausal woman on antihypertensive therapy (for example, amlodipine 5 mg daily), who also takes CoQ10 300 mg/day, then injects Vyleesi. The combined antihypertensive burden could amplify the post-injection BP fluctuation. The Vyleesi label already states the drug should not be used in women with uncontrolled hypertension or cardiovascular disease, and the transient BP rise could interact unpredictably with a significantly lowered baseline BP in this population.

Statin Users: A Nuance Worth Knowing

Women on statin therapy who are prescribed Vyleesi occupy a specific clinical intersection that is rarely discussed in product labeling. Statins (atorvastatin, rosuvastatin, simvastatin) reduce plasma CoQ10 concentrations by 16 to 54% depending on statin type and dose, according to a meta-analysis of 8 trials (N=267) [4]. This means statin users may actually have subtherapeutic CoQ10 levels even while supplementing, complicating any blood-pressure calculation. A 2022 position paper from the European Society of Cardiology working group on pharmacogenomics noted that statin-induced CoQ10 depletion is real but that routine supplementation to prevent statin-associated muscle symptoms (SAMS) lacks strong evidence from phase III trials [9]. Still, the depletion is real, and prescribers managing a woman on statin therapy plus Vyleesi should ask whether she is supplementing CoQ10, at what dose, and for how long.

The HealthRX clinical framework for this triad (statin + CoQ10 + bremelanotide) is:

1. Confirm baseline resting BP before the first Vyleesi injection.
2. Document statin type and dose to estimate CoQ10 depletion severity.
3. If CoQ10 dose exceeds 200 mg/day, advise morning dosing of CoQ10 and evening use of Vyleesi to maximize temporal separation.
4. Recheck BP at the first 1-hour post-injection check (standard protocol for new Vyleesi users).
5. Flag the combination for the prescriber if systolic BP drops below 90 mm Hg post-injection.

Practical Dosing and Timing Recommendations

Timing adjustments cannot eliminate a pharmacodynamic interaction, but they can reduce simultaneous peak exposure of two agents with overlapping cardiovascular effects.

CoQ10 Dosing Schedule on Vyleesi Days

CoQ10 is fat-soluble and best absorbed with a meal. Its half-life in plasma is approximately 33 hours for ubiquinone and slightly shorter for ubiquinol, meaning that a morning dose will still be active at night. However, peak plasma CoQ10 is typically reached 5 to 6 hours post-dose. Taking CoQ10 at breakfast and using Vyleesi in the evening (45 minutes before anticipated sexual activity, per the label) means the CoQ10 peak has passed and plasma levels are on the descending portion of the curve by the time bremelanotide is peaking at 1 hour post-injection.

This separation does not eliminate all CoQ10 cardiovascular effect, but it reduces the likelihood of simultaneous peak exposure.

Dose Ranges That Change the Risk Calculation

Not all CoQ10 doses carry equal cardiovascular relevance:

• 30 to 60 mg/day: general supplementation dose; BP effect at this level is minimal and not reliably shown in trials
• 100 to 200 mg/day: the range where meta-analysis data show mean systolic reductions of up to 11 mm Hg; moderate concern in hypertensive women
• 300 to 600 mg/day: used for fertility support; limited BP data at these doses specifically in normotensive premenopausal women, but caution is reasonable

Women taking 600 mg/day for fertility optimization represent the highest-dose scenario. At that dose, a conversation with the Vyleesi prescriber before the first injection is warranted, not because harm is certain but because BP monitoring should be planned.

Blood Pressure Self-Monitoring Protocol

A home blood pressure monitor (validated upper-arm device) gives actionable data. The check-in sequence for new Vyleesi users who also take CoQ10:

1. Measure BP at rest, 10 minutes before injection.
2. Measure again at 1 hour post-injection (the window for the initial BP rise per FDA labeling).
3. Note any symptoms: flushing, nausea, or light-headedness warrant a seated rest and a repeat measurement at 90 minutes.
4. If systolic BP remains above 165 mm Hg or drops below 85 mm Hg at either check, contact the prescriber before next use.

This protocol mirrors standard practice for any new antihypertensive-adjacent medication and adds minimal burden.

Safety Profile of Vyleesi: What the Trials Showed

Understanding Vyleesi's baseline safety data is necessary context for any supplement interaction discussion.

RECONNECT Trials (Phase III)

The two key RECONNECT trials enrolled 1,267 premenopausal women with acquired, generalized HSDD. Women were randomized to bremelanotide 1.75 mg or placebo and dosed on-demand (not daily) for 24 weeks [3]. Key safety findings:

• Nausea occurred in 40% of bremelanotide recipients vs. 1% on placebo; this is the most common adverse effect and the primary reason for discontinuation (8.9% vs. 0.2%).
• Flushing affected 20% of women receiving bremelanotide.
• Transient hyperpigmentation (focal, reversible) was reported in 1% of participants.
• No serious cardiovascular events were attributed to the drug in either trial.

The FDA approved Vyleesi in August 2019 with a REMS program initially required (later discontinued) and labeling that restricts use in women with cardiovascular disease [2].

Efficacy Data for Context

In RECONNECT Study 1 (N=627), women receiving bremelanotide reported a mean increase of 0.8 points on the Female Sexual Function Index (FSFI) desire subscale vs. 0.4 points with placebo (P<0.01). In RECONNECT Study 2 (N=640), the increase was 0.7 vs. 0.4 points (P<0.01) [3]. These are statistically significant but modest absolute differences, consistent with HSDD being a multifactorial condition that supplements, therapy, and relationship factors can also influence.

Who Should Be Especially Cautious?

Most premenopausal women taking CoQ10 at standard doses alongside Vyleesi face no clinically meaningful risk. Several subgroups deserve closer attention.

Women on Antihypertensive Therapy

Any woman whose baseline systolic BP is below 110 mm Hg on antihypertensive medication should discuss both CoQ10 and Vyleesi with her prescriber before the first injection. The combined effect of medication plus CoQ10 plus the post-injection fluctuation from bremelanotide could produce symptomatic hypotension in rare cases. This is not a reason to avoid the combination but a reason to plan monitoring.

Women Taking High-Dose CoQ10 for Fertility

Doses of 400 to 600 mg/day are increasingly used in reproductive medicine, particularly in women with diminished ovarian reserve, based on data suggesting mitochondrial support may improve oocyte quality. A small randomized trial (N=169) published in the Journal of Ovarian Research found that CoQ10 600 mg/day for 60 days before IVF improved fertilization rates in poor responders [10]. Women in this setting may be cycling through fertility treatments concurrently with managing HSDD, and their CoQ10 dose is high enough that a prescriber conversation is reasonable.

Women With Migraine or Cluster Headache Histories

Nausea from Vyleesi (40% incidence) and the vasodilatory effects of CoQ10 can both be associated with headache or migraine-adjacent symptoms. This is not a dangerous interaction but it may reduce tolerability of Vyleesi. Pre-medicating with prochlorperazine 25 mg suppository or ondansetron 4 mg (as some clinicians advise off-label) can mitigate nausea without interacting with CoQ10.

What to Tell Your Prescriber

Before your first Vyleesi injection, bring a complete supplement list including:

• CoQ10 dose and form (ubiquinone vs. Ubiquinol; ubiquinol has higher bioavailability at equivalent mg doses)
• Timing relative to meals and other medications
• Any concurrent antihypertensive, antidiabetic, or thyroid medications that also affect cardiovascular parameters

The FDA prescribing information does not list CoQ10 as a drug to avoid with Vyleesi. That absence reflects the lack of a harmful interaction, not inattention to the question. A clinician familiar with both agents can confirm that the combination is reasonable in most cases and advise personalized monitoring.

Key Takeaways for Clinical Practice

No evidence, mechanism, or case report suggests that CoQ10 causes a harmful pharmacokinetic interaction with bremelanotide (Vyleesi). The only plausible concern is a mild, additive blood-pressure effect that is relevant primarily in women who are already taking antihypertensive medication or using very high CoQ10 doses (300 mg/day or more). Standard practice is to take CoQ10 with morning meals and use Vyleesi in the evening per label instructions (45 minutes before anticipated activity), confirm resting BP before the first injection, and recheck at 1 hour post-injection on the initial dosing occasions.

Women on statins may have depleted CoQ10 levels that complicate the clinical picture, and that specific triad (statin plus CoQ10 supplementation plus bremelanotide) merits a brief prescriber conversation before starting Vyleesi. In the RECONNECT trials, the maximum mean systolic BP increase from bremelanotide was 6 mm Hg at 4 hours post-dose, and this returned to baseline within 12 hours in all participants [3]. At a CoQ10 dose of 100 mg/day in a normotensive premenopausal woman, the net cardiovascular impact of the combination is very likely to remain within safe limits.

If your resting systolic BP is consistently above 130 mm Hg before starting Vyleesi, address that with your prescriber before your first dose regardless of CoQ10 status.